Immunomodulatory effects of procainamide metabolites: their implications in drug-related lupus.
Evidence suggests that N-oxidized metabolites of procainamide may be responsible for the development of lupus-like symptoms associated with procainamide therapy. The human hepatic microsomal metabolism of procainamide has been previously reported to result in formation of the N-hydroxylamine derivative of procainamide (procainamide hydroxylamine [PAHA]). The objective of this study was to examine the effects of PAHA on human lymphocytes and adherent cells (monocytes and macrophages). When incubated with lymphocytes in whole blood, PAHA enhanced the response to mitogen and immunoglobulin secretion at lower concentrations (less than or equal to 4 mumol/L) but suppressed these functions at higher concentrations. The cytotoxic effects were nonselective for T lymphocytes and B lymphocytes and appeared to involve an interaction between PAHA and hemoglobin. When erythrocytes were removed or when hemoglobin was converted to carboxyhemoglobin, the suppressive effects of PAHA on lymphocytes were reduced. PAHA stimulated interleukin-1 production by adherent cells at 25 mumol/L but had no effect at lower concentrations. Superoxide anion release was unaffected by PAHA in "resting" adherent cells. Pretreatment with PAHA (2 mumol/L) diminished superoxide release in response to stimulation by phorbol myristate acetate (PMA) or latex bead phagocytosis but augmented superoxide release when coincubated with PMA or latex. These observations indicate that PAHA produces complex, concentration-dependent interactions with human immunoregulatory cells, and they suggest that the effects of PAHA on lymphocyte function may result from the further oxidation of PAHA by hemoglobin, perhaps to the nitroso form.
Adams
L E
LE
Department of Internal Medicine, University of Cincinnati, Medical Center, OH.
Sanders
C E
CE
Budinsky
R A
RA
Donovan-Brand
R
R
Roberts
S M
SM
Hess
E V
EV
D000328:Adult; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology; D007375:Interleukin-1 / Q000096:biosynthesis; D007840:Latex / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000276:immunology; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D008875:Middle Aged; D008934:Mitogens / Q000494:pharmacology; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D010587:Phagocytosis; D011342:Procainamide / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D013481:Superoxides / Q000097:blood
D006454:Hemoglobins; D007136:Immunoglobulins; D007375:Interleukin-1; D007840:Latex; D008934:Mitogens; D013481:Superoxides; C051948:procainamide 4-hydroxylamine; D011342:Procainamide